Visceral adipose tissue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
=== Side effects === Selective NRIs are generally well tolerated but the most common side effects reported are headache, dry mouth, abdominal pain, loss of appetite, nausea, vomiting, and drowsiness. An increase in heart rate and blood pressure have been reported but are usually not clinically important. Sexual adverse effects are mostly related to erectile dysfunction and decreased libido, but they are significantly less common than with serotonergic drugs. Other side effects are urinary retention, constipation, sweating and insomnia. What can be considered serious side effects are thoughts of suicide, aggressiveness and hallucinations.
Obesity is distributed unevenly across racial groups in the United States. Many racial minority populations disproportionately reside in low-income neighborhoods that can lack resources such as adequate healthcare, safe recreational areas, and grocery stores offering affordable, nutritious food options such as fresh fruits and vegetables. Furthermore, minority households can be more prone to obesity because of cultural food preferences and family norms. The higher prevalence of obesity among Black women compared to other demographics has been attributed to influence from cultural beauty ideals that tolerate or favor fuller body shapes. Hispanics have a high genetic susceptibility to obesity, as their Native American ancestors had adapted to a low-calorie diet, which predisposes Hispanics to obesity in the modern world, where high calorie foods are abundant.
The structure of somatostatin receptor antagonists is similar to that of the agonists. Some agonists were already approved by the FDA for clinical use, such as In-DTPA-octreotide and Ga-DOTATATE. Development started after the discovery of modifications that can be done to the octreotide group, an ssrt selective subtype agonist, to cause its agonistic effects to be lost and gain antagonistic effects. Different subtype receptor antagonists were later developed. Research has been done mostly on the sstr2 receptor antagonist, as the sstr2 receptor is expressed on most tumors. Somatostatin receptor antagonists are divided by generation based on the type of the subtype receptor antagonist. The first generation consists of sst2-ANT and BASS, which are sstr2 selective; and sst3-ODAN-8, which is selective for sstr3. After initial results of their increased sensitivity to neurocrine tumors appeared, ssrt2 selective antagonists that had even higher affinity were developed. These were LM3, JR10, and JR11, which make up the second generation. JR11 was shown to be the most effective among these 3 antagonists, and compounds that entered further clinical development to act as a PET imaging agent or therapeutic agent carried this subtype antagonist. The presence of a chelator coupled to the subtype antagonist was shown to affect the biological properties., by increasing the binding stability of the radionuclide to the rest of the compound, and increasing the binding affinity to the receptor by allowing conjugation of the radionuclide to the receptor.
==== Proposed joint US-USSR program ==== After a first US-USSR Dryden-Blagonravov agreement and cooperation on the Echo II balloon satellite in 1962, President Kennedy proposed on September 20, 1963, in a speech before the United Nations General Assembly, that the United States and the Soviet Union join forces in an effort to reach the Moon. Kennedy thus changed his mind regarding the desirability of the space race, preferring instead to ease tensions with the Soviet Union by cooperating on projects such as a joint lunar landing. Soviet Premier Nikita Khrushchev initially rejected Kennedy's proposal. However, on October 2, 1997, it was reported that Khrushchev's son Sergei claimed Khrushchev was poised to accept Kennedy's proposal at the time of Kennedy's assassination on November 22, 1963. During the next few weeks he reportedly concluded that both nations might realize cost benefits and technological gains from a joint venture, and decided to accept Kennedy's offer based on a measure of rapport during their years as leaders of the world's two superpowers, but changed his mind and dropped the idea since he lacked the same trust for Kennedy's successor, Lyndon Johnson. Some cooperation in robotic space exploration nevertheless did take place, such as a combined Venera 4–Mariner 5 data analysis under a joint Soviet–American working group of COSPAR in 1969, allowing a more complete drawing of the profile of the atmosphere of Venus. Eventually the Apollo–Soyuz mission was realized afterall, which furthermore laid the foundations for the Shuttle-Mir program and the ISS.
Sources: en.wikipedia.org
=== Germany === A ban on absinthe was enacted in Germany on 27 March 1923. In addition to banning the production of commercial trade in absinthe, the law went so far as to prohibit the distribution of printed matter that provided details of its production. The original ban was lifted in 1981, but the use of Artemisia absinthium as a flavouring agent remained prohibited. On 27 September 1991, Germany adopted the European Community's standards of 1988, which effectively re-legalised absinthe.
is constant throughout the change. Additionally, the Rahemi–Li model links the temperature dependence of Young’s modulus in metals to changes in the electron work function, providing a theoretical basis using a generalized Lennard-Jones potential.
== Behaviour == Most birds are diurnal, but some birds, such as many species of owls and nightjars, are nocturnal or crepuscular (active during twilight hours), and many coastal waders feed when the tides are appropriate, by day or night.
== Nomenclature == The first member of this gene family was called p10, in reference to the size and molecular weight (in kDa) of a protein from insect regenerating legs. The same protein (called Pam) was found in the adult antennae and legs from the two sexes of the American cockroach P. americana [2, 35]. Similar clones identified in Drosophila and Locusta in a search for olfactory genes referred to Olfactory-Sensory type D protein (OS-D or Pheromone Binding Protein A10) [20, 46-47]. Related clones identified in the antennae of the sphingid Manduca sexta were named sensory appendage proteins (SAPs) to distinguish them from a family of longer six-cysteine soluble proteins, i.e. odorant-binding proteins or OBPs [48]. Individual SAPs/CSPs have been designated in various ways: p10/Periplaneta americana (Nomura et al., 1992) [35], A10/Drosophila melanogaster (Pikielny et al., 1994) [46], OS-D/D. melanogaster (McKenna et al., 1994) [47], Pam/P. americana (Picimbon & Leal, 1999) [2], CSP/Schistocerca gregaria (Angeli et al., 1999) [3], SAP/Manduca sexta (Robertson et al., 1999) [48], Pherokine/D. melanogaster (Sabatier et al., 2003) [33], B-CSP/Acinetobacter baumannii, Macrococcus caseolyticus, Kitasatospora griseola, Escherichia coli (Liu et al., 2019) [24]. The protein family was renamed to chemosensory protein (CSP) by Angeli et al. after one (polyclonal) antibody against p10 labeled some sensory structures in the adult antennae of the desert locust Schistocerca gregaria [3]. The term “B-CSP” was used to refer to similar clones from bacterial (B) species [24].
Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid joined by an amide bond. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer. Contrary to previous assumptions that ceramides and other sphingolipids found in cell membrane were purely supporting structural elements, ceramide can participate in a variety of cellular signaling: examples include regulating differentiation, proliferation, and programmed cell death (PCD) of cells. The word ceramide comes from the Latin cera (wax) and amide. Ceramide is a component of vernix caseosa, the waxy or cheese-like white substance found coating the skin of newborn human infants.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.